Suppr超能文献

V600E 突变位置不当:同时患有真性红细胞增多症、毛细胞白血病和甲状腺腺瘤病例。

V600E mutation in the wrong place: a case of concomitant polycythemia vera, hairy cell leukemia, and thyroid adenoma.

机构信息

CRIMM, Centro di Ricerca e Innovazione per le Malattie Mieloproliferative, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.

Department of Experimental and Clinical Medicine, University of Florence, Denothe Excellence Center, Florence, Italy.

出版信息

Tumori. 2021 Dec;107(6):NP28-NP32. doi: 10.1177/0300891620986621. Epub 2021 Jan 12.

Abstract

BACKGROUND

Polycythemia vera (PV) is one of the Philadelphia-negative myeloproliferative neoplasms (MPN), characterized by a pan-myelosis with an erythroid-predominant proliferation mainly driven by somatic V617F gain-of-function mutation. Hairy cell leukemia (HCL) is a rare B-cell lineage lymphoproliferative disease (LPD) with a typic immunophenotypic profile. V600E, leading to constitutive activation of the RAF/MEK/ERK signalling pathway and increased cell proliferation, is identified as the driver mutation in almost all cases. Although the risk of developing an LPD is significantly increased in patients with MPN compared with the general population, few cases of co-occurring PV and HCL are reported to date. is one of the most frequently mutated oncogenes in human cancer and some point mutations were identified in multiple neoplasms in addition to HCL, including follicular and papillary thyroid adenoma and carcinoma.

CASE PRESENTATION

Here we report a molecular diagnostic challenge in a woman with a concomitant diagnosis of V617F PV, V600E HCL, and Q61K thyroid follicular adenoma.

CONCLUSION

In the age of molecular and precision medicine, this case underlines the importance of integrating molecular results with clinical, radiologic, cytologic, and histopathologic investigations.

摘要

背景

真性红细胞增多症(PV)是费城阴性骨髓增殖性肿瘤(MPN)之一,其特征为全髓增生,主要由体细胞 V617F 获得性功能突变驱动的红系增生。毛细胞白血病(HCL)是一种罕见的 B 细胞谱系淋巴增殖性疾病(LPD),具有典型的免疫表型特征。V600E 导致 RAF/MEK/ERK 信号通路的组成性激活和细胞增殖增加,几乎所有病例中都可识别为驱动突变。虽然与普通人群相比,MPN 患者发生 LPD 的风险显著增加,但迄今为止报道的同时发生 PV 和 HCL 的病例很少。BRAF 是人类癌症中最常突变的致癌基因之一,除了 HCL 之外,还在多种肿瘤中发现了一些点突变,包括滤泡性和乳头状甲状腺腺瘤和癌。

病例介绍

我们在此报告了一名女性患者的分子诊断挑战,该患者同时诊断为 V617F PV、V600E HCL 和 Q61K 甲状腺滤泡性腺瘤。

结论

在分子和精准医学时代,该病例强调了将分子结果与临床、影像学、细胞学和组织病理学研究相结合的重要性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验